Bristol Myers (BMY) Receives a Hold from BMO Capital


In a report released yesterday, Alex Arfaei from BMO Capital maintained a Hold rating on Bristol Myers (NYSE: BMY), with a price target of $54. The company’s shares closed yesterday at $50.88, close to its 52-week low of $49.96.

According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.8% and a 73.0% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Eli Lilly & Co.

Currently, the analyst consensus on Bristol Myers is a Moderate Buy with an average price target of $60.86, a 19.6% upside from current levels. In a report issued on October 8, Guggenheim also initiated coverage with a Hold rating on the stock with a $70 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $70.05 and a one-year low of $49.96. Currently, Bristol Myers has an average volume of 6.42M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts